Abstract
Apoptotic cells are cleared from the body principally through recognition and engulfment by neighboring phagocytes, a process known as efferocytosis. During efferocytosis, phagocytes are recruited to the site/activated by “find me” signals released from apoptotic cells, precisely identify apoptotic cells by the recognition of “eat me” signals on the apoptotic cell surface, and engulf the apoptotic cells to prevent secondary necrosis and inflammation. Thus, efferocytosis is critical for tissue homeostasis in normal physiology. However, efferocytosis of apoptotic tumor cells—performed by tumor-associated macrophages—suppresses immunity within the tumor microenvironment and limits the antitumor response. This phenomenon is further exacerbated in tumor residual disease because of the high apoptotic cell burden generated by cytotoxic therapies. Blocking efferocytosis could be a powerful approach to boost tumor immunogenicity, particularly as a combination approach with cytotoxic therapies that produce many apoptotic cells, but little is currently known about the immune response to efferocytosis. Moreover, there is a dearth of in vivo models available to study the immunologic and therapeutic consequences of blocking efferocytosis in tumor residual disease.
Here, we describe a model that enables in vivo studies of tumor immunology in the aftermath of cytotoxic therapy with an emphasis on the impact of efferocytosis. Orthotopic HER2+ mammary tumors are established in immune-competent mice, followed by a single administration of lapatinib, a receptor tyrosine kinase inhibitor of HER2, to the mice that induces widespread, transient apoptosis in the tumor microenvironment. In the days following lapatinib treatment, agents that block efferocytosis such as BMS-777607 are administered. Tissue is collected from cohorts of mice at day 2 (after lapatinib treatment only) to assess apoptosis, day 8 (after lapatinib treatment followed by blockade of efferocytosis) to assess the immune response to apoptosis and efferocytosis, and day 28 (after 4 consecutive weeks of treatment) to assess therapeutic efficacy. This model enables mechanistic studies of tumor immunology in residual disease as well as therapeutic efficacy studies of targeted agents that disrupt efferocytosis.
Key words
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Elliott MR, Chekeni FB, Trampont PC et al (2009) Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance, Nature:461. https://doi.org/10.1038/nature08296
Truman LA, Ford CA, Pasikowska M et al (2008) CX3CL1/fractalkine is released from apoptotic lymphocytes to stimulate macrophage chemotaxis. Blood 112. https://doi.org/10.1182/blood-2008-06-162404
Fadok VA, Voelker DR, Campbell PA et al (1992) Exposure of phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophages. J Immunol 148
Borisenko GG, Matsura T, Liu S-X et al (2003) Macrophage recognition of externalized phosphatidylserine and phagocytosis of apoptotic Jurkat cells—existence of a threshold, Arch Biochem Biophys:413. https://doi.org/10.1016/S0003-9861(03)00083-3
Ravichandran KS (2010) Find-me and eat-me signals in apoptotic cell clearance: progress and conundrums. J Exp Med 207. https://doi.org/10.1084/jem.20101157
Graham DK, DeRyckere D, Davies KD, Earp HS (2014) The TAM family: phosphatidylserine-sensing receptor tyrosine kinases gone awry in cancer. Nat Rev Cancer 14. https://doi.org/10.1038/nrc3847
Willingham SB, Volkmer J-P, Gentles AJ et al (2012) The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proc Natl Acad Sci 109. https://doi.org/10.1073/pnas.1121623109
Kojima Y, Volkmer J-P, McKenna K et al (2016) CD47-blocking antibodies restore phagocytosis and prevent atherosclerosis. Nature 536. https://doi.org/10.1038/nature18935
Brown S, Heinisch I, Ross E et al (2002) Apoptosis disables CD31-mediated cell detachment from phagocytes promoting binding and engulfment. Nature 418. https://doi.org/10.1038/nature00811
Park D, Tosello-Trampont A-C, Elliott MR et al (2007) BAI1 is an engulfment receptor for apoptotic cells upstream of the ELMO/Dock180/Rac module. Nature 450. https://doi.org/10.1038/nature06329
Miyanishi M, Tada K, Koike M et al (2007) Identification of Tim4 as a phosphatidylserine receptor. Nature 450. https://doi.org/10.1038/nature06307
Park S-Y, Jung M-Y, Kim H-J et al (2008) Rapid cell corpse clearance by stabilin-2, a membrane phosphatidylserine receptor. Cell Death Diff 15. https://doi.org/10.1038/sj.cdd.4402242
Akakura S, Singh S, Spataro M et al (2004) The opsonin MFG-E8 is a ligand for the αvβ5 integrin and triggers DOCK180-dependent Rac1 activation for the phagocytosis of apoptotic cells. Exp Cell Res 292. https://doi.org/10.1016/j.yexcr.2003.09.011
Feng W, Yasumura D, Matthes MT et al (2002) Mertk triggers uptake of photoreceptor outer segments during phagocytosis by cultured retinal pigment epithelial cells, J Biol Chem:277. https://doi.org/10.1074/jbc.M107876200
Sanjuan MA, Dillon CP, Tait SWG et al (2007) Toll-like receptor signalling in macrophages links the autophagy pathway to phagocytosis. Nature 450. https://doi.org/10.1038/nature06421
Martinez J, Almendinger J, Oberst A et al (2011) Microtubule-associated protein 1 light chain 3 alpha (LC3)-associated phagocytosis is required for the efficient clearance of dead cells. Proc Natl Acad Sci 108. https://doi.org/10.1073/pnas.1113421108
Martinez J, Cunha LD, Park S et al (2016) Noncanonical autophagy inhibits the autoinflammatory, lupus-like response to dying cells. Nature 533. https://doi.org/10.1038/nature17950
Elliott MR, Ravichandran KS (2016) The dynamics of apoptotic cell clearance. Dev Cell 38. https://doi.org/10.1016/j.devcel.2016.06.029
Birge RB, Boeltz S, Kumar S et al (2016) Phosphatidylserine is a global immunosuppressive signal in efferocytosis, infectious disease, and cancer. Cell Death Differen 23. https://doi.org/10.1038/cdd.2016.11
Cook RS, Jacobsen KM, Wofford AM et al (2013) MerTK inhibition in tumor leukocytes decreases tumor growth and metastasis. J Clin Investig 123. https://doi.org/10.1172/JCI67655
Stanford JC, Young C, Hicks D et al (2014) Efferocytosis produces a prometastatic landscape during postpartum mammary gland involution. J Clin Investig 124. https://doi.org/10.1172/JCI76375
Werfel TA, Elion DL, Rahman B et al (2019) Treatment-induced tumor cell apoptosis and secondary necrosis drive tumor progression in the residual tumor microenvironment through MerTK and IDO1. Cancer Res 79. https://doi.org/10.1158/0008-5472.CAN-18-1106
Muller WJ, Sinn E, Pattengale PK et al (1988) Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene, Cell:54. https://doi.org/10.1016/0092-8674(88)90184-5
Siegel PM, Dankort DL, Hardy WR, Muller WJ (1994) Novel activating mutations in the neu proto-oncogene involved in induction of mammary tumors, Mol Cell Biol:14. https://doi.org/10.1128/MCB.14.11.7068
Garrett JT, Olivares MG, Rinehart C et al (2011) Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase. Proc Nat Acad Sci 108. https://doi.org/10.1073/pnas.1016140108
Vaught DB, Stanford JC, Young C et al (2012) HER3 is required for HER2-induced Preneoplastic changes to the breast epithelium and tumor formation. Cancer Res 72. https://doi.org/10.1158/0008-5472.CAN-11-3594
Konecny GE, Pegram MD, Venkatesan N et al (2006) Activity of the dual kinase inhibitor Lapatinib (GW572016) against HER-2-overexpressing and Trastuzumab-treated breast cancer cells. Cancer Res 66. https://doi.org/10.1158/0008-5472.CAN-05-1182
Bergers G, Brekken R, McMahon G et al (2000) Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2. https://doi.org/10.1038/35036374
Zhang W, DeRyckere D, Hunter D et al (2014) UNC2025 , a potent and orally bioavailable MER/FLT3 dual inhibitor. J Med Chem 57. https://doi.org/10.1021/jm500749d
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2022 The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Werfel, T.A. (2022). Assessment of the Immune Response to Tumor Cell Apoptosis and Efferocytosis. In: Barcenilla, H., Diaz, D. (eds) Apoptosis and Cancer. Methods in Molecular Biology, vol 2543. Humana, New York, NY. https://doi.org/10.1007/978-1-0716-2553-8_5
Download citation
DOI: https://doi.org/10.1007/978-1-0716-2553-8_5
Published:
Publisher Name: Humana, New York, NY
Print ISBN: 978-1-0716-2552-1
Online ISBN: 978-1-0716-2553-8
eBook Packages: Springer Protocols